The price tag of Biogen's new Alzheimer's medication Aduhelm has raised criticism and concern in the US. Soon, authorities will decide the extent of the available support schemes and the patient groups that will be offered the medication, according to Bloomberg News.
The price for one year of treatment has been set at USD 56,000. Moreover, patients will need regular scans to monitor the effect of the treatment and potential side effects. Thus, this can quickly turn into a costly affair.